Scientists at Washington University in St Louis have developed a breath test that quickly identifies those who are infected with the virus that causes Covid-19. The device requires only one or two breaths and provides results in less than a minute.
The same group of researchers recently published a paper in Nature Communications about an air monitor they had built to detect airborne SARS-CoV-2 – the virus that causes Covid-19 – within about five minutes in hospitals, schools and other public places.
The new study is about a breath test that could become a tool for use in doctors’ offices to quickly diagnose people infected with the virus. If and when new strains of Covid-19 or other airborne pathogenic diseases arise, such devices could also be used to screen people at public events. The researchers said the breath test also has potential to help prevent outbreaks in situations where many people live or interact in close quarters – for example aboard ships, in nursing homes, in residence halls at colleges and universities or on military bases.
‘With this test, there are no nasal swabs and no waiting 15 minutes for results, as with home tests,’ said Rajan K Chakrabarty, the Harold D Jolley career development associate professor of energy, environment and chemical engineering at the McKelvey School of Engineering. ‘A person simply blows into a tube in the device and an electrochemical biosensor detects whether the virus is there. Results are available in about a minute.’
The biosensor used in the device was adapted from an Alzheimer’s-disease-related technology developed by scientists at Washington University School of Medicine in St Louis to detect amyloid beta and other Alzheimer’s-disease-related proteins in the brains of mice. The School of Medicine’s John R Cirrito, a professor of neurology, and Carla M Yuede, an associate professor of psychiatry used a nanobody, an antibody from llamas, to detect the virus that causes Covid-19.
Chakrabarty and Cirrito said the breath test could be modified to simultaneously detect other viruses, including influenza and respiratory syncytial virus. They also believe they can develop a bio-detector for any newly emerging pathogen within two weeks of receiving samples of it.
‘It’s a bit like a breathalyser test that an impaired driver might be given,’ Cirrito said. ‘And, for example, if people are in line to enter a hospital, a sports arena or the White House Situation Room, 15-minute nasal swab tests aren’t practical, and PCR tests take even longer. Plus, home tests are about 60–70 per cent accurate and they produce a lot of false negatives. This device will have diagnostic accuracy.’
The researchers began working on the breath test device – made with 3D printers – after receiving a grant from the National Institutes of Health during the first year of the pandemic in August 2020. Since receiving the grant, they’ve tested prototypes in the laboratory and in the Washington University Infectious Diseases Clinical Research Unit. The team continues to test the device, to further improve its ability to detect the virus in people.
For the study, the research team tested Covid-positive individuals, each of whom exhaled into the device two, four or eight times. The breath test produced no false negatives and gave accurate reads after two breaths from each person tested. The clinical study is ongoing to test Covid-positive and -negative individuals to further test and optimise the device.
The researchers also found that the breath test successfully detected several different strains of SARS-CoV-2, including the original strain and the omicron variant. Their clinical studies are measuring active strains in the St Louis area.
To conduct the breath test, the researchers insert a straw into the device. A patient blows into the straw and aerosols from the person’s breath collect on a biosensor inside the device. The device is then plugged into a small machine that reads signals from the biosensor and in less than a minute, the machine reveals a positive or negative finding of Covid-19.
Clinical studies are continuing and the researchers plan to employ the device in clinics beyond Washington University’s Infectious Diseases Clinical Research Unit. In addition, Y2X Life Sciences, a New York-based company, has an exclusive option to license the technology. That company has consulted with the research team from the beginning of the project and during the device’s design stages to facilitate possible commercialisation of the test in the future.
The research has been published in ACS Sensors.